Emergent Biosolutions, Inc. (EBS) Stake Lessened by OxFORD Asset Management LLP
OxFORD Asset Management LLP reduced its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 41.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,349 shares of the biopharmaceutical company’s stock after selling 20,485 shares during the quarter. OxFORD Asset Management LLP owned approximately 0.07% of Emergent Biosolutions worth $961,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Sei Investments Co. boosted its stake in shares of Emergent Biosolutions by 97,546.2% during the second quarter. Sei Investments Co. now owns 38,082 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 38,043 shares during the period. Bank of America Corp DE lifted its stake in Emergent Biosolutions by 31.0% in the first quarter. Bank of America Corp DE now owns 234,902 shares of the biopharmaceutical company’s stock worth $6,821,000 after acquiring an additional 55,626 shares during the period. Congress Asset Management Co. MA lifted its stake in Emergent Biosolutions by 9.8% in the second quarter. Congress Asset Management Co. MA now owns 52,080 shares of the biopharmaceutical company’s stock worth $1,766,000 after acquiring an additional 4,632 shares during the period. Federated Investors Inc. PA lifted its stake in Emergent Biosolutions by 3.4% in the second quarter. Federated Investors Inc. PA now owns 245,002 shares of the biopharmaceutical company’s stock worth $8,308,000 after acquiring an additional 8,098 shares during the period. Finally, First Trust Advisors LP lifted its stake in Emergent Biosolutions by 169.2% in the second quarter. First Trust Advisors LP now owns 53,149 shares of the biopharmaceutical company’s stock worth $1,802,000 after acquiring an additional 33,403 shares during the period. 85.35% of the stock is owned by hedge funds and other institutional investors.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $40.50, for a total value of $1,012,500.00. Following the completion of the transaction, the chairman now directly owns 1,555,216 shares of the company’s stock, valued at approximately $62,986,248. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 15,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $37.21, for a total value of $558,150.00. Following the completion of the transaction, the chief executive officer now directly owns 219,134 shares of the company’s stock, valued at $8,153,976.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 230,227 shares of company stock valued at $8,793,970. 16.50% of the stock is currently owned by corporate insiders.
Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.31 on Friday. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 25.68 and a beta of 1.26. Emergent Biosolutions, Inc. has a 1-year low of $24.47 and a 1-year high of $41.46. The company has a 50-day moving average of $38.54 and a 200-day moving average of $33.90.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.13). The firm had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. On average, equities research analysts expect that Emergent Biosolutions, Inc. will post $1.54 EPS for the current fiscal year.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Finally, Zacks Investment Research lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.00.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.